Top news of the day across the health care landscape.
Novartis AG and Bayer AG are among nearly 30 drug manufacturers planning to raise US prices of their products in January, Reuters reported. According to the article, other manufacturers set to increase prices at the start of 2019 include Allergan Plc, GlaxoSmithKline Plc, Amgen Inc, AstraZeneca Plc, and Biogen Inc. Twenty-eight manufacturers filed notifications with California agencies in November disclosing that they planned to raise prices in 60 days or longer, the article noted.
The Centers for Medicare and Medicaid Services said nearly 8.5 million individuals enrolled in the Affordable Care Act as of last Saturday’s deadline, the Associated Press reported. According to the article, the preliminary number showed that enrollment was down approximately 4%, despite predictions of a steeper loss in sign-ups. However, the number of new customers remained down by approximately 15% compared with last year, the article reported.
Supernus Pharmaceuticals announced that its drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage trial including adolescents, according to Reuters. The article reported that the drug, SPN-812, showed statistically significant improvements in the symptoms of ADHD among individuals aged 12 to 17 years. SPN-812 also met the main goal in 2 other late-stage trials testing the treatment in children, although analysts said the results failed to stand out from existing treatment options, Reuters said.